Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies



Rating:

Share or cite this content

Citations should be made in the following way:
J. Hurst (London, United Kingdom), M. Han (Ann Arbor, MI, United States of America), B. Celli (Boston, MA, United States of America), M. Bafadhel (Oxford, United Kingdom), M. Jenkins (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America), M. Patel (Cambridge, United Kingdom). Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial. 790

Member's Comments

No comment yet.

Related content which might interest you: Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Indacaterol/glycopyrronium (IND/GLY) improves lung function irrespective of gender baseline differences in patients with COPD: A pooled analysis from the IGNITE Program Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Patients’ adherence to treatment: How does it changes in 1 year after finishing of the participation in trial? Source: Annual Congress 2013 –New treatments and old dilemmas in the clinical management of lung diseases Year: 2013 Regional analysis of COPD exacerbation rates in the DYNAGITO trial Source: International Congress 2019 – Exacerbations of airway diseases Year: 2019 Are there patient characteristics associated with improvements or worsening in the placebo arm of COPD tlinical trials? Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Impact of morning symptoms experienced by COPD patients on exacerbation risk, rescue inhaler usage and normal daily activities Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Relationship of baseline or annual change of clinical parameters on mortality in patients with COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care Year: 2011 Direct cost analysis of COPD patients: A 1 year follow-up study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Improving morning activities in COPD patients with budesonide/formoterol: Assessment of data from two randomised trials using minimal important differences from a morning activities questionnaire Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Effect of high or low-medium accumulated dose regimes of systemic corticosteroids for hospitalised patients with exacerbated chronic obstructive pulmonary disease: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 The relationship between symptom scores and medication adherence in stable COPD patients Source: International Congress 2017 – COPD management Year: 2017 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015